Results 161 to 170 of about 1,365,887 (339)

A Rare Case of Synchronous Multiple Primary Malignancies of the Pancreas, Skin, and Thyroid. [PDF]

Case Rep Oncol Med
Barsoum M, Pepeljugoski CA.
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Synchronous Primary Gallbladder Cancer and Ipsilateral Renal Cell Carcinoma: A Case Report. [PDF]

Cureus
Alobaidi SK.
europepmc   +1 more source

Multiple primary malignant neoplasms. I. Introduction and presentation of data

Cancer, 1961
C. Moertel, M. Dockerty, A. Baggenstoss
semanticscholar   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Integrated diagnostic evaluation of multiple malignant neoplasms via ^99mTc-MDP three-phase bone imaging: A case report. [PDF]

Oncol Lett
Lian JY, Lu JL, Zheng HY, Yuan SX, Zhang JS.   +4 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Risk Factors beyond Chemotherapy Exposure for Secondary Myeloid Neoplasms after Hematologic Cancers: A SEER-Based Study. [PDF]

Cancer Res Commun
Singh A, Hahn T, Mishra R, Herr MM, Thota S.   +4 more
europepmc   +1 more source

Behaviour of multiple primary neoplasms. [PDF]

BMJ, 1977
T V, Taylor, B, Torrance
openaire   +2 more sources

Statistical methods for studying multiple primary malignant neoplasms

Cancer, 1977
B. Schoenberg, M. Myers
semanticscholar   +1 more source